Resistance-mutation pattems in the reverse transcriptase (RT) and protease ' genes of HIV-1 were analyzed in 22 patients who had been extensively prekeated and who failed to respond to highly active antiretroviral therapy (HAART). The number of mutations ranged from 8 to 19 (median, 13): 4 to 12 (median, 6) mutations in the RT gene, and 4 to 8 (median, 7) mutations in the protease gene. In the RT gene, the most frequent resistance mutations were found at codons 215 (loo%), 41 (95%), 67 (91%), and 210 (77%). Multidrug-resistant mutation pattems including QI5 1M and insertion mutations at codon 69, which confer cross-resistance to the different nucleoside anaIogue RT inhibitors were detected in l and 3 patients, respectively; l patient with insertion mutation displayed a NGQCV sequence at codons 67 to 70. In the protease gene, the most frequent mutations were found at codons 63 (95%), 10 (86%), 90(86%), 71(77%), 46 @O%), 36 (45%), and 84 (45%). Genotypic resistance to zidovudine, saquinavir, and indinavir was found in 100% of the patients. All patients showed also resistance or possible resistance to stavudine, abacavir, ritonavir, and nelfíavir. Mutations conferring genotypic resistance to nonnucleoside analogue RT inhibitors ("RTIs) were found in 12 (80%) of the "RTI-experienced patients and 1 of 7 NNRTI-naive patients. Our results indicate that failure of HAART in the patients extensively pretreated results from the multipliçity of RT and protease mutations that confer genotypic resistance to almost all available antiretroviral drugs. In these patients, genotypic resistance tests confirm the lack of altemative salvage therapy strategies based on the currently available antiretroviral drugs. Key Words: MutationsGenotypic resistance-Highly active antiretroviral therapy-Treatment fdure.
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Highly active antiretrovírd therapy (HAART), based on the combination of three or more antiretroviral drugs including protease inhibitors (PIS), is the current standard far treatment of HIV-1-infected patients (1) . In antiretroviral-naive patients, use of these potent drug regimens results in a dramatic decrease in virus replication, be-cause a drop of HIV-1 RNA levels in plasma below the limit of detection is observed with a high frequency (2) .
Nucleoside analogue reverse transcriptase inhibitor (NFtTO-based monotherapies or two-drug combination therapies that were administered before PI availability are not sufficiently potent to suppress HIV-1 replication (3, 4) . Given that viral replication in the presence of antiviral drugs leads to selection and development of HIV-1 variants that harbor resistance mutations, response ta HAART is frequently impaired in patients pretreated with a drug regimen considered as suboptimal in terms of virologic efficacy, and HAART failure is more frequently observed in these patients (5, 6) .
TO assess the extent of resistance to antiviral drugs in patients heavily pretreated who did not respond to HAART, we analyzed the sequence of RT and protease genes of HIV-1 in patients who had been treated for several years by successive antiretroviral therapies, including suboptimal regimens, and who thus presented with failure of HAART.
PATIENTS AND METHODS

Patients
The present analysis included 22 consecutive HIV-l-infected patients recruited between September 1998 and August 1999 who fulm e d the following criteria: l> they have been extensively (>2 years) pretreated by antiretroviral drugs regimens including suboptimal treatments by NRTI monotherapy and/or dual combination therapy; 2) they presented after failure of at least two consecutive HAART regimens, and 3) they maintained a high level of viral replication defined by a plasma viral load >30,000 copieslml. They comprised 18 males and 4 females. Their median age was 42 years (range, 11.067. all patients underwent a dual NRTI combination regimen for a medïan duration of 49 weeks (range, 1-131 weeks). Patients have been treated by HAART for a median duration of 115 weeks (range, 69-186 weeks). Drugs administered, cumulative duration of treatment with each drug, and time since discontinuation of these drugs are detailed in Table 1 . All patients have received therapy with at least four NRTk (median, 5; range, 4-6) and two PIS (median, 4; range: 2-5); 15 of these patients have experienced one (n = 8) or two (n = 7) non-NRTIs (NNRTI).
Reverse Transcriptase and Protease Gene Sequencing
HIV-1 RNA was extracted from plasma using the QIAamp viral RNA klt (Qiagen, Courtaboeuf, France) and reverse-transcribed using the Expand RT (Roche Diagnostic Systems, Meylan, France). A 2219-bp DNA fragment encompassing the RT and protease genes was amplified by seminested polymerase chain reaction (PCR). The primers G25Rev (5'-GCAAGAGmTGGCTGAAGCAATGAG) and In3 (5'-TCTATBCCATCTAAAAATAGTACmC(=TGATTCC) were used for the.first round of amplification and the primers AV150 (5'-GTGGAAAGGAAGGACACCAAATGAAAG) and In3 were used for the second round. Seven overlapping fkagments were sequenced using the primers AV150, In5 (5'-AATITTCCCA'ITAGTCCTATTGAN-ACTGTACCAG), POlMO (5'-TCCCTCAGATCACTCTTTGGCA), POIMI (5'-GTI'AAACAATGGCCATTGACAGA ), POI M2 (5'-GAT-TTGTATGTAGGATCTGA) for the positive strand and the primers Pol M4 (5'-CTATTAGCTGCCCCATCTACATA) and PolM6 (5'-CTTTGATAAAACCTCCAAIT) for the negative strand. Sequences were analyzed with the ABI prism 377 automatic sequencing system (Applied Biosystems, des Upis, France) and the amino acid sequences were compared with the HIV-1, RT and protease sequences. By sequencing these overlapping fragments, each nucleotide position in the RT and protease genes was analyzed by two to four independent sequence reactions. DNA sequences have been submitted to Gedank under the accession numbers AJ405947 to AJ405968.
Sequence Interpretation
'
Inteqmtation of genotype in terms of drug-resistance was based on an algorithm established by the "Resistance" group of the French National Agency for AIDS Research (ANRS) (7) . Mutations indexed in the ANRS report are: M41L, A62V, K65R, D67NIEIS, T69D, insertion at codon 69, IC70R, L74V, V75MIsIAIIA, F77L, Y115F, F116Y, Q151M, M184W, LZlOW, T215Y/F, and K219QE for NRTIs ; A98G, LlOOI, KlOlE, K103N, V106A, VIOSI, YISlCfl, Y188UC, G190A/S, P225H, and P23Q for NNRTIs, and L l O W , KILORIM, D30N, M361, M4611L, I47V, G4SV, EOV, I54V/L, L63P, A71V/T, G73S, V771, V82A/F/T/S, I84V, N88S/D, and L9OM for PIS. Taking into account the major or minor character of the different mutations i n term of resistance, the algorithm provided in the ANRS report distinguished pattems of mutations confemng "resistance" from pattems confening "possible resistance" to a given antiretroviral drug (see Appendix).
RESULTS
RT and Protease Gene Mutations
Resistance mutations in the RT and protease genes were detected in all patients. As shown in Table 2 , the number of resistance mutations detected in individual patients ranged from 8 to 19 (median, 13). The number of resistance mutations in the RT gene ranged from 4 to 12 (median, 6): all patients showed mutations (3-11) confering resistance to NRTIs and 13 of them showed mutations (1-4) conferring resistance to "RTIs. The number of resistance mutations on the protease gene ranged from 4 to 8 (median, 7).
The mutations most frequently detected in the RT gene were T215YE (loo%), M41L (95%), D67N (91%), and L210W (77%). Prevalences of the zalcitabine (ddC)-specific mutation T69D, lamivudine (3TC)-specific mutation M184V, stavudine (d4T)-specific mutation V75M//T, and didanosine (dd1)-specific mutation M74V were 32%, 21%, 9%, and 5%, respectively. One patient presented the multidrug resistant (MDR) mutation pat-
between codons 69 and 70 was observed in 3 patients: one SS insertion (patient no. 15), one SV insertion (patient no. 16), and a NGQCV sequence instead of the DSTK sequence at codons 67 to 70.
Among the RT gene mutations conferring resistance to " R T I s , Y181C (27%), K103N (23%), and G190A (18%) were the most frequently detected. u Cumulative duration of treatment (weeks) with each drug is indicated within parentheses. ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; d4T, stavudine; 3TC, lamivudine; ABC, abaca+, NVP, nevirapine; DLV, delavirdine; EFV, efavirenz; SQV, saquina+, IDV, indinavir; RTV, ritonavir; NFV, nelfinavir; APV, amprenavir; ABT, ABT-378. 
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In the protease gene, the most prevalent mutations were L63P (95%), L l O W (86%), L9OM (86%), A71VlT (77%), M46I (50%), M36I (45%), and 184V (45%).
.
Genotypic Resistance
The pattems of genotypic resistances presented by individual patients are given in Table 2 . All patients showed genotypic resistance to ZDV, saquinavir (SQV), and indinavir (IDV); they also showed resistance or possible resistance to d4T, abacavir (ABC), ritonavir (RTV),
. and nelfinavir ("V); 91% of them showed resistance or possible resistance to amprenavir (APV) (Fig. 1) . Genotypic resistance to ddI, ddC, 3TC, and ABT-378 (ABT)
were less frequently found. Among the 15 patients experienced with "RTIs, 12 (80%) showed resistance to this class of compounds. Genotypic resistance to "R-TIS was also found in one NNRTI-naive patient (#4). In the same way, we observed that 4 of 9 (44%) patients naive to ddC had the T69D ddC-specific mutation (patients #3, #8, #17, and #19). 
DISCUSSION
In this study, we analyzed mutation patterns of the RT and protease genes of HIV-1 in patients extensively pretreated by successive antiretroviral therapies who failed to respond to HAART. Multiple mutations conferring resistance to RT and protease inhibitors were identified in all patients. In nearly 60% of these patients, the mutations patterns indicated genotypic resistance or pos- 
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sible resistance to every drug included in HAART, whereas in the remainder of these patients, the number of drugs not concerned by genotypic resistance remained very limited. It has been previously reported that failure of HAART is predicted by the number of resistance mutations in RT and protease genes (8, 9) . Results obtained in our patients strongly suggest that HAART failure resulted from the resistance of HIV-1 to the drugs administered and not from other causes such as inadequate drug exposure due to pharmacologic factors or suboptimal patient adherence to treatment (10) . All patients had genotypic resistance to ZDV and also demonstrated resistance or possible genotypic resistance to d4T and ABC because it was considered that the presence of three or more ZDV-specific mutations including T215YF confers possible resistance to d4T and ABC (427,11-13). We also observed a high frequency of genotypic resistance to PIS. Resistance concerned not only the more widely used PIS such as SQV, IDV, RTV, and NFV but also APV and ABT. Indeed, all patients but one were naive to APV and 91% of them had genotypic resistance or possible resistance to APV. In the same way, all patients were naive to ABT and 45% of them had genotypic resistance to ABT. The presence of secondary mutations that confer cross resistance to different PIS accounted for this resistance. In particular, the mutation I84V is known to confer a cross-resistance to various PIS, including APV and ABT (14J5). Therefore, our results are in agreement with previous studies indicating that the multiplicity of RT and protease mutations confers crossresistance to almost all available antiretroviral drugs, including compounds in clinical development (16, 17) .
All patients were experienced with ddI but only 5
showed genotypic resistance to this compound. Genotypic resistance to ddI involved a L74V mutation (1 patient), an insertion at codon 69 (3 patients) and a MDR pattern involving codons 62, 75, 77, 116, and 151 (1 patient). The low prevalence of the dd1-specific resistance mutation L74V in patients with combination therapy has been previously observed (18, 19) . However, it has been shown that ddI monotherapy can promote development of ZDV-specific resistance mutations (20, 21) and that the antiviral effect of NRTI combinations containing ddI is diminished in patients infected with HIV-I strains harboring ZDV-specific resistance mutations (4,ll) . Therefore, despite the low frequency of genotypic resistance to ddI in heavily treated patients, further investigation is needed to assess the efficacy of this drug in patients infected with HIV-1 variants harboring multiple resistance mutations in the RT gene.
All these patients were experienced with 3TC but only 27% of them had the 3TC-specific mutation M184V. The I L relatively low proportion of patients harboring the M184V mutation can be explained because 77% of these patients had discontinued 3TC at the time of testing. Indeed, the M184V mutation impairs viral fitness and the M184V variants are rapidly replaced by a HIV-1 population with wild-type sequence at codon 184 after stopping therapy with.3TC (22, 23) .
The mutation T69D, considered as ddC-specific, was observed in 32% of patients. This relatively low frequency can be explained because only 59% of patients were experienced with ddC and that all had discontinued ddC treatment for 26 to 170 weeks. Interestingly, we also detected the T69D mutation in 44% of the ddC-naive patients. This observation suggests that cross resistance to ddC conferred by mutation at codon 69 can be promoted by protracted administration of other NRTIs. In the same way, we observed genotypic resistance to " R T I s in one of the seven NNRTI-naive patients. To our knowledge, cross-resistance between NRTIs and " R T I s has not been reported. Therefore, further investigation at a larger scale is needed to study genotypic resistance to " R T I s in "RTI-naive patients extensively treated by NRTIs.
An insertion between codons 69 and 70 was detected for 3 (14%) patients. Insertions in this region-located in the "fingers" domain involved in the nucleoside triphosphate binding site of the enzyme-are known to confer multinucleoside analogue resistance (24, 25) . In 1 such patient, we identified a novel sequence characterized by a single amino acid insertion associated with a set of other substitutions between codons 67 and 70, giving a NGQCV sequence instead of the DSTK consensus sequence. A novel genotype characterized by a single amino acid insertion at codon 69, associated with five other substitutions located between codons 64 and 74 has, been recently described and recognized as conferring multiple resistance to NRTIs (26) . We therefore considered that the NGQCV sequence at codons 67 to 70 conferred multinucleoside analogue resistance, but this remains to be confirmed by phenotypic analysis.
It has been shown that in patients with antiretroviral therapy failure, genotypic-resistance testing is of interest for choosing a therapeutic alternative (18) . However, results obtained in the present study indicate that in patients extensively pretreated, failure of HAART results from resistance to almost all available antiretroviral drugs. Therefore, genotypic resistance tests seem to lack usefulness in these patients to propose a salvage therapy based on the currently available antktroviral drugs. These tests, however, remain probably useful to identify patients who could benefit from experimental treatments by new classes of compounds such as fusion inhibitors.
APPENDIX
Intelpretation of HIV-1 reverse-lranscriptase and protease mutations according to the algorithm established by the Resistance group of the ANRS (1999 report 171). ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; d4T, stavudine; ABC, abaca+, NVP, nevirapine; DLV, delavirdine; EFV, efavirenz; SQV, saquinavir; IDV, indinavir; RTV, ritonavir, NFV, nelfina+, APV, amprenavir.
Genotvuic resistance to nucleoside analogue reverse-tmnscriptase inhibitors
